Independent intelligence for the laboratory world

Roche Endotrophin Assay Reaches Nordic Bioscience cobas e801 Lab

Nordic Bioscience says Rocheโ€™s Endotrophin research prototype assay is now available on cobas e801 analyzers at its CLIA laboratory.

Roche cobas e801 analyzer installed at Nordic Bioscienceโ€™s laboratory for Endotrophin research assay testing. Source: Nordic Bioscience via PR Newswire.

Press release summary

HERLEV, Denmark โ€” Nordic Bioscience said Nov. 16 that Roche Diagnostics has made an Endotrophin research prototype assay available on cobas e801 analyzers at Nordic Bioscienceโ€™s CLIA laboratory.

The sandwich immunoassay measures intact Endotrophin, a 77-amino-acid signaling peptide released during formation of type VI collagen. Researchers are studying the biomarkerโ€™s relationship to fibrosis, inflammation and adverse outcomes in cardiovascular, kidney and metabolic disease. Nordic Bioscience said Endotrophin has been measured in more than 50,000 patients across cardio-kidney-metabolic studies.

The prototype is the second biomarker from the companiesโ€™ collaboration to reach a Roche platform, following the CE-marked Elecsys PRO-C3 test. The release cited studies associating elevated Endotrophin with mortality and adverse outcomes in heart failure with preserved ejection fraction, as well as kidney-function decline. The assay remains a research prototype and is not presented as an authorized diagnostic test.

Why it matters: Moving a biomarker assay onto a high-throughput clinical laboratory analyzer can make it easier to incorporate into multicenter studies and drug-development programs. Laboratories should distinguish this availability milestone from clinical validation or regulatory clearance and evaluate analytical performance, specimen requirements and study-specific controls before use.

Read the original Nov. 16 release from Nordic Bioscience via PR Newswire.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *